This Article Full Text Full Text (PDF) Supplemental material Other Versions of this Article: JVI.00401-08v1 82/14/7223    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Cubillos, C. Articles by Blanco, E. PubMed PubMed Citation Articles by Cubillos, C. Articles by Blanco, E.

 Previous Article  |  Next Article 

Journal of Virology, July 2008, p. 7223-7230, Vol. 82, No. 14
0022-538X/08/$08.00+0     doi:10.1128/JVI.00401-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Enhanced Mucosal Immunoglobulin A Response and Solid Protection against Foot-and-Mouth Disease Virus Challenge Induced by a Novel Dendrimeric Peptide ^,

Centro de Investigación en Sanidad Animal, INIA, Valdeolmos, 28130 Madrid, Spain,¹ Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, 08003 Barcelona, Spain,² Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Canto blanco, 28049 Madrid, Spain³

Received 25 February 2008/ Accepted 21 April 2008

The successful use of a dendrimeric peptide to protect pigs against challenge with foot-and-mouth disease virus (FMDV), which causes the most devastating animal disease worldwide, is described. Animals were immunized intramuscularly with a peptide containing one copy of a FMDV T-cell epitope and branching out into four copies of a B-cell epitope. The four immunized pigs did not develop significant clinical signs upon FMDV challenge, neither systemic nor mucosal FMDV replication, nor was its transmission to contact control pigs observed. The dendrimeric construction specifically induced high titers of FMDV-neutralizing antibodies and activated FMDV-specific T cells. Interestingly, a potent anti-FMDV immunoglobulin A response (local and systemic) was observed, despite the parenteral administration of the peptide. On the other hand, peptide-immunized animals showed no antibodies specific of FMDV infection, which qualifies the peptide as a potential marker vaccine. Overall, the dendrimeric peptide used elicited an immune response comparable to that found for control FMDV-infected pigs that correlated with a solid protection against FMDV challenge. Dendrimeric designs of this type may hold substantial promise for peptide subunit vaccine development.

Published ahead of print on 30 April 2008.

Supplemental material for this article may be found at http://jiv.asm.org/.